Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Summary

The goal of this clinical research study is to find the best dosing schedule of a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that may help improve immune response in patients that had Stage II or Stage III melanoma and are free of the disease. The safety and tolerability of this drug combination will also be studied. Researchers also want to collect long-term follow-up information.

Timeline

Start

2009-03-10

Primary completion

2017-02-24

Completion

2017-02-24

Drugs

Indications